

# Appendices

## Special Considerations in Clinical Practice

### A. Self-Report Relaxation Training Form

When we teach the relaxation response, the typical protocol requires the patient to visit the office between one and three times per week. This limited frequency would make it difficult to realize the desired therapeutic effect of a cultivated lower arousal status. Therefore, patients commonly receive relaxation training “homework.” This usually consists of asking the patient to employ the relaxation response once or twice a day. In order to provide a useful forum for communications and to improve compliance, it is highly desirable to have patients complete a relaxation training report from each time they practice the relaxation response. They are then asked to return the completed forms to the therapist at the beginning of each office session. The therapist then uses these forms as a means of reviewing patients’ progress.

Following this introduction is a sample relaxation report form that may be used for reporting on the progress made in home relaxation training.

**Relaxation Report Form**

Name: \_\_\_\_\_ Time Started \_\_\_\_\_

Date: \_\_\_\_\_ Time Finished \_\_\_\_\_

Beginning SURS\* \_\_\_\_\_ (before the relaxation exercise begins)

Ending SURS \_\_\_\_\_ (after the relaxation exercise has ended)

Were you able to relax? YES NO (Circle one)

If "No", why not? \_\_\_\_\_

Did your mind wander? YES NO

If "Yes", what were you distracted by? \_\_\_\_\_

Did you experience anything unusual? YES NO

If "Yes", what? \_\_\_\_\_

Is there anything else you would like to report? \_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

\*The SURS (Subjective Units of Relaxation) indication is a method by which you may indicate your subjective levels of relaxation. A SURS of 10 will be indicative of a dreamlike state of profound relaxation; a SURS of 5 is indicative of how you believe the "average" person feels on an "average" day; and a SURS of 1 is indicative of a panic attack. Choose any number between 1 and 10, inclusive, to indicate your beginning and ending SURS levels.

## **B. Physically Passive Neuromuscular Relaxation**

Earlier in this text, we stated that “neuromuscular relaxation” is the term usually reserved for isotonic and isometric contractions of the striated musculature designed to teach the client to relax. The entire discussion on neuromuscular relaxation has addressed that type of physically active procedure. By far the greater part of the literature has been generated on this active form of neuromuscular relaxation—hence our emphasis on reviewing that form. There does exist, however, what may be considered a physically passive form of neuromuscular relaxation. Here, we address that form of relaxation.

Physically passive neuromuscular relaxation fundamentally consists of having the patient focus sensory awareness on a series of individual striated muscle groups and then relax those muscles through a process of direct concentration. In the passive neuromuscular relaxation procedure described here, there is no actual muscular contraction initiated as part of the relaxation cycle—hence “passive” neuromuscular relaxation.

The physically passive neuromuscular relaxation procedure may be considered a form of mental imagery and directed sensory awareness. Mental imagery as a therapeutic intervention has a long and effective history for a wide range of clinical problems (see Leuner, 1969; Sheehan, 1972). When applied to the reduction of muscle tension, the basic mechanism involved in passive neuromuscular relaxation appears to be useful in tension reduction. In a review of investigations into the role of neuromuscular relaxation in general tension reduction, Borkovec et al. (1978) conclude: “Apparently, frequent attempts to relax while focusing on internal sensations are sufficient to promote tension reduction” (p. 527). In our own clinical experience, we have found passive neuromuscular relaxation to be quite effective in reducing subjective as well as electromyographically measured muscle tension.

There do appear to be several distinct advantages and disadvantages when comparing passive neuromuscular relaxation with a physically active form of neuromuscular relaxation. Passive neuromuscular relaxation has the advantage of having no potential limitations based on physical handicaps, as compared with neuromuscular relaxation that involves actual muscle tensing. Another advantage is the fact that the patient can execute a passive protocol without distracting others or drawing attention to him- or herself. Such is obviously not the case with a protocol that involves actual muscle contraction. A final advantage is that a passive protocol generally takes much less time to complete (usually half the time). The major disadvantage in using a passive form of neuromuscular relaxation is that, like meditation or other forms of mental images, it leaves the patient more vulnerable to distracting thoughts. This may be a significant drawback when using a passive protocol with obsessive-type patients or those who have a tendency to get bored easily.

Let us now examine one sample passive protocol (written as if being spoken directly to the patient). The “preparation for implementation” phase will be funda-

mentally the same as for the physically active form of neuromuscular relaxation, except for few alterations (refer to Chap. 12). In Step 1 of the preparation for implementation (precautions), the precautions are the same as those described for general relaxation. However, the special precautions for meditation prevail here, as opposed to those for the physically active neuromuscular relaxation. The physically passive component here dictates this alteration. Steps 2 through 4 may remain the same. Steps 5 through 8 may be omitted because of their reference to the actual tensing of muscles. The patient is instructed to breathe normally, in a relaxed manner.

### **Background Information**

It has long been known that muscle tension can lead to stress and anxiety—thus, if you can learn to reduce excessive muscle tension, you will reduce excessive stress and anxiety.

What you are about to do is relax the major muscle groups in your body. You can do this by simply focusing your attention on each set of muscles that I describe. Research has shown that with *patience* and *practice*, you can learn to achieve a deeply relaxed state by simply concentrating on relaxing any of the various muscle groups in your body.

First, you should find a quiet place, without interruptions or glaring lights and a comfortable chair or bed to support your weight. Feel free to loosen restrictive clothing and remove glasses and contact lens if you desire.

### **Actual Instructions**

OK, let's begin. I'd like you to close your eyes and get as comfortable as you can. Let the chair or bed support all your weight. Remember, your job is to concentrate on allowing the muscles that I describe to relax completely.

### **Chest and Stomach**

I'd like you to begin by taking a deep breath. Ready? Begin... (*pause 3 s*) and now exhale as you feel the tension leave your chest and stomach. Let's do that one more time. Ready? Begin... (*pause 3 s*) and now relax and exhale as the tension continues to leave and your chest and stomach are relaxed.

### **Head**

I'd like you to focus your attention on the muscles in your head. Now begin to feel those muscles relax as a warm wave of relaxation begins to descend from the top of your head. Concentrate on the muscles in your forehead. Now begin to allow those muscles to become heavy and relaxed. Concentrate as your forehead becomes heavy and relaxed (*pause 10 s*). Now switch your focus to the muscles in your eyes and

cheeks and begin to allow them to become heavy and relaxed. Concentrate as your eyes and cheeks become heavy and relaxed (*pause 10 s*). Now switch your focus to the muscles in your mouth and jaw. Allow those muscles to become heavy and relaxed. Concentrate as your mouth and jaw become heavy and relaxed (*pause 10 s*).

### **Neck**

Now you can begin to feel that wave of relaxation descend into the muscles of your neck. Your head will remain relaxed as you now shift your attention to your neck muscles. Allow your neck muscles to become heavy and relaxed. Concentrate as your neck becomes heavy and relaxed (*pause 10 s*).

### **Shoulders**

Now you can begin to feel that wave of relaxation descend into your shoulder muscles. Your head and neck muscles will remain relaxed as you now shift your attention to your shoulder muscles. Allow your shoulder muscles to become heavy and relaxed. Concentrate as your shoulders become heavy and relaxed (*pause 10 s*).

### **Arms**

Now you can begin to feel that wave of relaxation descend into your arms. Your head, your neck, and your shoulders will remain relaxed as you now shift your attention to the muscles in both your arms. Allow both your arms to become heavy and relaxed. Concentrate as your arms become heavy and relaxed (*pause 10 s*).

### **Hands**

Now you can begin to feel that wave of relaxation descend into your hands. Your head, your neck, your shoulders, and your arms will remain relaxed as you now shift your attention to the muscles in both your hands. Allow both your hands to become heavy and relaxed. Concentrate as your hands become heavy and relaxed (*pause 10 s*).

### **Thighs**

Now you can begin to feel that wave of relaxation descend into your thighs. Your head, your neck, your shoulders, your arms, and your hands will remain relaxed as you now shift your attention to the muscles in both your thighs. Allow both your thighs to become heavy and relaxed. Concentrate as your thighs become heavy and relaxed (*pause 10 s*).

## Calves

Now you can begin to feel that wave of relaxation descend into your calves. Your head, your neck, your shoulders, your arms, your hands, and your thighs will remain relaxed as you now shift your attention to the muscles in both your calves. Allow both your calves to become heavy and relaxed. Concentrate as your calves become heavy and relaxed (*pause 10 s*).

## Feet

Now you can begin to feel that wave of relaxation finally descend into your feet. The entire rest of your body will remain relaxed as you now shift your attention to the muscles in both your feet. Allow both your feet to become heavy and relaxed. Concentrate as your feet become heavy and relaxed (*pause 10 s*).

## Closure

All the major muscles in your body are now relaxed. To help you remain relaxed, simply repeat to yourself each time you exhale, “I am relaxed.” Take the next few minutes and continue to relax as you repeat to yourself, “I am relaxed”... “I am relaxed” (*pause about 5 min*).

## Reawaken

Now I want to bring your attention back to yourself and the world around you. I shall count from 1 to 10. With each count, you will feel your mind become more and more awake, and your body become more and more responsive and refreshed. When I reach 10, open your eyes, and you will feel the *best* you’ve felt all day—you will feel alert, refreshed, full of energy, and eager to resume your activities. Let’s begin: 1–2 You are beginning to feel more alert, 3–4–5 you are more and more awake, 6–7 now begin to stretch your hands and feet, 8– now begin to stretch your arms and legs, 9–10 open your eyes, *now!* You feel alert, awake, your mind is clear and your body refreshed.

On concluding the initial passive neuromuscular procedure, inform the patient that he or she can use this procedure to relax once or, preferably, twice a day—before lunch and before dinner. Other times can also be useful as well, particularly as an aid for sleeping.

In summary, Appendix B has presented the clinician with a physically passive alternative form of neuromuscular relaxation, not as a prescription, but as an example of how such a protocol might be created. This option is designed simply to expand the clinician’s arsenal of stress-reduction interventions to meet the idiosyncratic needs of individual patients. The ultimate assessment of clinical suitability remains with the clinician and should be made on an individual, case-by-case basis.

## C. Vascular Headaches and Vasoactive Substances

Many vascular headaches, including the classical migraine, can be induced by vasoactive stimuli. These stimuli interact with what may be a biogenic predisposition for vascular spasticity so as to set the stage for a vascular headache. More specifically, vasoactive stimuli are factors that have the ability to stimulate the sympathetic neural constituency of thusly innervated blood vessels. Through what may be either a vasospastic or a singular vascular rebound phenomenon, these stimuli are believed to have the capability to induce a vascular headache syndrome, including the classical migraine syndrome.

The primary vasoactive substances include the following:

1. Tyramine (a pressor amine)
2. Monosodium glutamate
3. Sodium nitrate
4. Histamine
5. Bright light that creates glare
6. Changes in barometric pressure, especially rapid declines
7. Strenuous physical exercise
8. Loud noise
9. Some sympathomimetics. (Despite the fact that sympathomimetic pharmaceuticals are prescribed to treat vascular headaches, the initial ingestion of some “hidden” or naturally occurring sympathomimetics may be sufficient to induce a vasospasm.)

Foods that are relatively high in vasopressor action include the following:

1. Liver
2. Most cheeses
3. Caviar
4. Sausages
5. Coffee (depending upon quantity)
6. Tea (depending upon quantity)
7. Chocolate (depending upon quantity)
8. Marinated herring
9. Hot dogs (if containing nitrates)
10. Chianti and other red wines
11. Many foods that contain brewer’s yeast
12. Fava beans
13. Many fermented or overripened foods

These lists are provided as general information for the practicing clinician. They should not be used to prescribe medication or to alter the dietary regimen of patients. Rather, the information contained herein is designed to serve as a general guide to assist in formulating diagnostic and/or treatment impressions for appropriate medical and nutritional consultation.

## D. The Etiology of Panic Attacks: Nonpsychological Factors

Panic attacks represent a very specific form of pathological stress response. Shader (1984) has suggested prevalence in the United States to be 2.0–4.7%. Any clinician who treats stress- and anxiety-related disorders will invariably be confronted with patients presenting some form of panic disorder and its predictable pattern of subsequent behavioral avoidance.

Panic attacks are characterized by paroxysmal episodes of ANS hyperfunction usually combined with cognitive–affective symptoms that include dissociation, depersonalization, a generalized morbid fear, fear of dying, fear of losing control, and/or intense emotional manifestation. Proprioception is often interrupted, thus leaving the patient neuromuscularly unstable. Panic attacks typically may last but several minutes, although some attacks could last more than an hour, depending upon etiology.

Although it is widely known that panic attacks can be initiated by psychological factors, it is less widely known that panic attacks are sometimes secondary to variant medical/physiological conditions. Before treating a patient with panic-like symptomatology via psychotherapeutic or psychopharmacological interventions, the clinician should first attempt to determine to what degree medical or physiological factors serve as the etiological basis for the attacks.

Listed below are the most common primary medical/physiological factors that may give rise to secondary panic attacks; clinicians should be sensitive to these factors when constructing a medical history for the patient with some form of panic syndrome.

Acute hypoglycemia may serve as a panicogenic stimulus. It is well-established that the arcuate and ventromedial hypothalamic nuclei contain receptors responsible for the neurological monitoring of glucose. Buckley (1985) has argued that acute hypoglycemic inhibition of the hypothalamic glucoreceptor mechanisms prevents the release of the neurotransmitter beta endorphin and its inhibitory effect upon the panic-related neural networks of the locus ceruleus. When this inhibitory effect is removed, the locus ceruleus becomes far more likely to be massively depolarized. If such depolarization were to occur, a noradrenergically mediated panic attack would most likely result.

1. It has been suggested that some women will suffer panic-like symptoms at the point in their menstrual cycle when progesterone reaches its zenith. This point is usually within 7 days of the onset of menses. This conclusion is based upon the hypothesis that, for some, high levels of progesterone can act as a panicogenic substance (see Carr & Sheehan, 1984).
2. Vigorous anaerobic exercise is believed to be able to induce panic in those patients biologically inclined to suffer from panic disorders. One of the by-products of anaerobic exercise is lactic acid. Pitts and McClure (1967) found that some individuals manifest a biogenic hypersensitivity to lactate (a relative to

lactic acid) and this hypersensitivity is manifested in the form of panic attacks. Thus, factors that lead to a rise in lactic acid may be associated with panic.

3. According to Gorman, Liebowitz, and Klein (1984), there exist several medical disorders that either mimic or induce panic attacks. They include:

- (a) Hyperthyroidism
- (b) Hypothyroidism
- (c) Mitral valve prolapse
- (d) Cardiac arrhythmias
- (e) Pheochromocytoma
- (f) Drug or alcohol withdrawal
- (g) Coronary insufficiency
- (h) Amphetamine overdose
- (i) Caffeine overdose

In summary, the assessment of any medical or physiological factors known to serve in the primary etiology of the panic syndrome seems a reasonable course of action prior to treating a patient with a history of panic-like symptoms.

## E. How Do You Cope with Stress?

### *A Self-Report Checklist Designed for Health Education Purposes*

**DIRECTIONS:** There are many ways to cope with the stress in your life. Some coping techniques are more effective than others. The purpose of this checklist is to help you, the reader, assess how effectively you cope with the stress in your life. Upon completing this checklist, you will have identified many of the ways you choose to cope with stress, while at the same time, through a point system, ascertaining the relative desirability of the coping techniques that you now employ. This is a health education survey, not a clinical assessment instrument. Its sole purpose is to inform you of how you cope with the stress in your life.

In order to complete the checklist, simply follow the instructions given for each of the items listed below. When you have completed all of the 14 items, place your total score in the space provided.

- \_\_\_ 1. Give yourself 10 points if you feel that you have a supportive family.
- \_\_\_ 2. Give yourself 10 points if you actively pursue a hobby.
- \_\_\_ 3. Give yourself 10 points if you belong to some social or activity group that meets at least once a month (other than your family).
- \_\_\_ 4. Give yourself 15 points if you are within 5 pounds of your “ideal” body-weight, considering your height and bone structure.
- \_\_\_ 5. Give yourself 15 points if you practice some form of “deep relaxation” at least three times a week. Deep relaxation exercises include meditation, imagery, yoga, etc.
- \_\_\_ 6. Give yourself 5 points for each time you exercise 30 min or longer during the course of an average week.
- \_\_\_ 7. Give yourself 5 points for each nutritionally balanced and wholesome meal you consume during the course of an average day.
- \_\_\_ 8. Give yourself 5 points for each time you do something that you really enjoy, “just for yourself,” during the course of an average week.
- \_\_\_ 9. Give yourself 10 points if you have some place in your home that you can go to in order to relax and/or be by yourself.
- \_\_\_ 10. Give yourself 10 points if you practice time-management techniques in your daily life.
- \_\_\_ 11. Subtract 10 points for each pack of cigarettes you smoke during the course of an average day.
- \_\_\_ 12. Subtract 5 points for each evening during the course of an average week that you take any form of medication or chemical substance (including alcohol) to help you sleep.
- \_\_\_ 13. Subtract 10 points for each day during the course of an average week that you consume any form of medication or chemical substance (including alcohol) to reduce your anxiety or just calm you down.

\_\_\_\_ 14. Subtract 5 points for each evening during the course of an average week that you bring work home; work that was meant to be done at your place of employment.

\_\_\_\_ Total Score

Now that you've calculated your score, consider that the higher your score, the greater your health-promoting coping practices. A "perfect" score would be around 115. Scores in the 50–60 range are probably adequate to cope with most common sources of stress.

Also keep in mind that items 1–10 represent adaptive, health-promoting coping strategies, and items 11–14 represent maladaptive, health-eroding coping strategies. These maladaptive strategies are self-sustaining because they do provide at least some temporary relief from stress. In the long run, however, their utilization serves to erode one's health. Ideally, health-promoting coping strategies (items 1–10) are the best to integrate into your lifestyle and will ultimately prove to be an effective preventive program against excessive stress.

## References

- Borkovec, T., Grayson, J., & Cooper, K. (1978). Treatment of general tension: Subjective and physiological effects of progressive relaxation. *Journal of Consulting and Clinical Psychology, 46*, 518–526.
- Buckley, R. (1985, November). *Post-prandial hypoglycemic anxiety*. Paper presented to the 32nd Annual Meeting of Psychosomatic Medicine, San Francisco, CA.
- Carr, D., & Sheehan, D. (1984). Panic anxiety: A new biological model. *The Journal of Clinical Psychiatry, 45*, 323–330.
- Gorman, J., Liebowitz, M., & Klein, D. (1984). *Panic disorder and agoraphobia*. Kalamazoo, MI: Upjohn.
- Leuner, H. (1969). Guided affective imagery. *American Journal of Psychotherapy, 23*, 4–21.
- Pitts, F., & McClure, J. (1967). Lactate metabolism in anxiety neurosis. *New England Journal of Medicine, 277*, 1329–1336.
- Shader, R. (1984). Epidemiologic and family studies. *Psychosomatics, 25*(Suppl.), 10–15.
- Sheehan, P. (1972). *The function and nature of imagery*. New York: Academic Press.

# Index

## A

- AA. *See* Alcoholics anonymous (AA)
- AACC. *See* American Association of Christian Counselors (AACC)
- AACL. *See* Affect adjective checklist (AACL)
- AAPB. *See* Association of Biofeedback and Psychophysiology (AAPB)
- Academic stress, effect on immune function, 88
- Acceptance, 93, 166, 167, 169, 208, 342, 386–388
- Acceptance and Commitment Therapy (ACT), 166–169, 279
- Accreditation Council for Graduate Medical Education (ACGME), 373
- Acetylcholine, 19, 25, 32  
neuronal pathways of, 19
- ACGME. *See* Accreditation Council for Graduate Medical Education (ACGME)
- Achilles, 4, 128
- Acquired immunodeficiency syndrome (AIDS)  
neuromuscular relaxation adjunct treatment for, 89  
prayer-based therapy for, 340  
sense of control in, 165
- ACSM. *See* American College of Sports Medicine (ACSM)
- ACT. *See* Acceptance and Commitment Therapy (ACT)
- Acta, Inc., 445
- ACTH. *See* Adrenocorticotropic hormone (ACTH)
- Addictive disorders, 177, 277  
limbic hypersensitivity associated with, 177
- Adenosine triphosphate (ATP), 305, 349
- ADHD. *See* Attention-deficit hyperactivity disorder (ADHD)
- Adjustment disorders  
causes of, 174  
as disorders of arousal, 60, 174
- Adolescents, 88, 119, 136, 148, 240, 337, 357, 372, 390, 394, 395  
trauma exposure in, 337
- Adrenal cortex, 33, 35, 36, 440  
location of, 33, 35
- Adrenal cortical axis, 35–38, 47
- Adrenal gland, 33, 74, 443  
anatomy of, 443
- Adrenaline. *See* Epinephrine
- Adrenal medullary catecholamine axis, 37
- Adrenergic sympathetic response, 34
- Adrenocortical activity, 208  
meditation-related decrease in, 208
- Adrenocorticotropic hormone (ACTH), 35, 36, 41, 62, 111, 112, 444
- Aerobic fitness training, 305  
guidelines for, 303, 306
- Affect, 8, 10, 28, 31, 36, 39, 42, 55, 61, 75, 78, 86, 94, 121, 149, 152, 159, 160, 162, 165, 168, 176, 186, 225, 278, 279, 282, 283, 298, 339, 349, 371, 391, 404–406, 409, 448
- Affect adjective checklist (AACL), 118, 119, 123

- Affective disorders, 92, 93, 95, 177, 183, 193  
 limbic hypersensitivity associated with, 177
- Affective integration, 27, 28, 61
- Aggression, 71, 129, 392  
 gastrointestinal response to, 71
- Aggressive personality, 134, 136
- Agoraphobia, 227
- AIDS. *See* Acquired immunodeficiency syndrome (AIDS)
- Alarm reaction, 54, 440
- Alcoholics anonymous (AA), 341, 342
- Alcoholism  
 disability-adjusted life years associated with, 4  
 electroencephalographic biofeedback treatment for, 276  
 meditation treatment for, 85
- Aldosterone, 36, 94
- Alexander, F., 58, 127, 128, 138
- All-cause mortality, 302, 305, 338, 339
- Allergy, 76
- Alopecia areata, 78, 94
- Alprazolam (Xanax<sup>®</sup>), 319, 320
- Alzheimer's disease  
 caregivers, 88  
 oxidative stress-related, 354
- American Association of Christian Counselors (AACC), 340
- American Association of Fitness Directors in Business and Industry, 295
- American College of Sports Medicine (ACSM), 303, 304, 307, 308, 310
- American Heart Association, 307, 309
- Amherst College, 295
- Amitriptyline (Elavil<sup>®</sup>), 323, 324
- Amphetamines, 7, 27, 177
- Amygdala  
 anatomy of, 410  
 role in emotional arousal, 176  
 role in emotional memory processing, 23, 176
- Anafranil (clomipramine), 323, 324
- Ananias, 4
- Animal magnetism, 255, 256, 263
- Anterior thalamic nuclei, role in emotional arousal, 175, 176
- "Antiarousal" therapy, 60, 185, 186
- Antibodies, 80–84, 86, 88, 91
- Antidepressants, 321–325, 328, 421
- Antidiuretic hormone, 38
- Antigens, 76, 78–82, 84, 86
- Antihistamines, 324, 327, 328
- Antioxidants, 354–357, 359, 361  
 recommended daily allowances of (RDA), 355
- Antipsychotic medications, 326–327
- Anxiety  
 caffeine-related, 92, 358  
 chronic, 12, 59, 180, 320  
 diffuse, 91, 92, 239, 298  
 as disorder of arousal, 181, 182  
 disorders  
*Diagnostic and Statistical Manual of Mental Disorders* classification of, 174  
 kindling in, 183  
 meditation treatment for, 209  
 subcortically-initiated arousal and reactivity associated with, 177  
 symptomatology of, 174  
 effect of exercise on, 226, 230, 277, 298, 299  
 gamma-aminobutyric acid in, 318  
 gastrointestinal response to, 58, 71, 358  
 homeostasis in, 41, 181, 182  
 in human immunodeficiency virus-positive individuals, 89  
 hypnosis as treatment for, 258–262  
 pharmacologic therapy for, 176  
 prevalence of, 4, 407  
 relaxation training-related, 165, 190, 240  
 striated muscle tension during, 238, 239, 298
- Appetite, 6, 36, 70, 318, 352, 357, 360, 394  
 differentiated from hunger, 352, 361
- Applied psychophysiology and biofeedback, 283
- Appraisal, 5, 7, 27–31, 121, 144, 148, 158–160, 390, 407, 432
- Arousal *See also* Stress response  
 biochemical basis of, 182  
 charged, 30  
 cultivated low, 134  
 disorders of, 181, 182  
 emotional, 30, 32, 62, 175, 176, 189  
 etiological and/or sustaining components of, 113, 174, 178, 185, 186, 193  
 as "latent taxon" of disease, 174  
 limbic hypersensitivity in, 30, 59, 60, 177, 179–182, 192  
 neuromuscular relaxation control of, 193, 450  
 nonspecific, 29, 30

- during physical exercise, 308
  - physical expression of, 293
  - physiological, biogenic stressors-related, 7
  - positive effects of, 335
  - preparatory, 10
  - psychiatric, 59, 174–179, 192
  - psychophysiological, 12, 55, 56, 61, 186, 188, 308
  - relationship with performance, 11, 189
  - somatic, 59, 108, 178, 179, 192
  - suppression of, 57
  - treatment for, 173
  - Asclepiades, 295
  - Aspartate, 411
    - in posttraumatic stress disorder, 411
  - Asper, S., 445
  - Association of Biofeedback and Psychophysiology (AAPB), 283
  - Asthma bronchial, 76–77, 94, 240, 258
    - electrodermal biofeedback treatment for, 278
  - Atarax® (hydroxyzine), 327
  - Atenolol (Tenormin®), 327
  - Atherosclerosis, 339
    - lifestyle-based management of, 339
  - Ativan® (lorazepam), 319, 320
  - Atlas, C., 238
  - ATP. *See* Adenosine triphosphate (ATP)
  - Attention-deficit hyperactivity disorder (ADHD), 205, 210, 276, 1277, 282, 319, 349, 351, 358
  - Autism, 326, 354
  - Autonomic-excitation, 56
  - Autonomic hyperfunction, 59
  - Autonomic lability, 59, 121
  - Autonomic learning theory, 55
  - Autonomic nervous system
    - activation thresholds of, 32, 180, 183
    - classical conditioning of, 269
    - emotional arousal-related activation of, 32
    - hyperactivity of, 420
    - neural activation function of, 32
    - operant conditioning of, 269
  - Avoidant personality, 135
  - Axons, 18–20
- B**
- Bacterial infections, 86
    - as peptic ulcer cause, 70
  - BAI. *See* Beck Anxiety Inventory (BAI)
  - Bandura, A., 148, 149, 152, 160, 188, 189, 282, 284
  - Barber Suggestibility Scale, 262
  - Barbiturates, 327–328
  - Barometric pressure change, 74, 279
    - vasoactive response to, 74
  - Baroreceptors, 74, 279
  - Basmajian, J.V., 270, 271, 284
  - Baudouin, C., 256
  - B cells, 80–82
    - trauma-related decrease in, 82
  - Beck Anxiety Inventory (BAI), 119–120
  - Beck, A.X., 119, 158
  - Beliefs, 44, 106, 130, 133, 137–139, 144, 145, 147–149, 152, 160, 161, 166, 168, 201, 299, 333–342, 386, 412–414, 420, 450
    - irrational, disputation of, 160, 161, 168, 299
  - Benadryl® (diphenhydramine), 327
  - Benson, H., 11, 30, 59–63, 173, 174, 186–189, 192, 202–204, 206, 209–212, 215, 262, 277, 293, 333, 334, 342, 411, 414
  - Benzodiazepines, 176, 319–321, 324–328, 374, 416
  - Bereavement, 85, 88, 94, 119, 385, 386, 388–392, 396
    - effect on immune function, 85, 94
  - Berger, H., 275
  - Bernstein, D.A., 237, 251
  - Beta-adrenergic blocking agents, 327, 328
  - Beta-carotene, 356–358
  - beta lipotropin, 35
  - Bhalla, V., 237, 450
  - Binet, A., 256
  - Binge eating, 210, 352
    - meditation treatment for, 210
  - Biofeedback
    - ADHD, 276, 282
    - adverse reactions to, 280
    - alpha-theta feedback, 276
    - definition of, 267, 270
    - dynamic three-dimensional technology, 270
    - feedback loop in, 267, 284
    - heart rate variability (HRV), 278–280, 284
    - history of, 269, 280
    - for homeostatic regulation, 58
    - modalities of, 268, 271–280, 282
    - neurofeedback, 276, 283, 284
    - neurotherapy, 276, 283
    - paraspinal, 272
    - patient selection for, 191, 212, 278, 280–283
    - patient's self-efficacy in, 134, 282, 284
    - patient-therapist relationship in, 189

- Biofeedback (*cont.*)  
 pelvic floor muscle training, 272, 273  
 quantitative EG (QEEG), 276  
 resonant frequency, 279  
 therapist's errors in use of, 139, 281  
 Tourette syndrome, 278  
 urinary incontinence, 270, 272, 273
- Biofeedback Certification Institute  
 of America, 283
- Biofeedback Research Society, 269
- Blood  
 flow, 34, 39, 75, 77, 109, 110, 123, 227,  
 268, 273, 293, 297, 304  
 peripheral, measurement of, 109, 110,  
 123, 297  
 immune system components in, 82  
 pressure (*see also* Hypertension;  
 Hypotension)  
 as acute index of stress response, 109  
 diastolic, 109, 110, 192  
 effect of religious beliefs on, 339  
 measurement of, 72, 109, 110, 123,  
 188, 303  
 meditation-related decrease in, 280  
 during stress response and exercise,  
 94, 109, 123, 297, 318  
 systolic, 110, 339
- Body temperature, exercise-induced elevation  
 in, 298
- Booth-Kewley, S., 131
- Borkovec, T., 190, 237, 240
- Borysenko, J., 173, 186, 188, 189, 210
- Bowlby, J.  
 disorganization, 387  
 numbness, 387  
 reorganization, 387  
 yearning, 387
- Boyle, R., 17
- Braid, J., 256
- Brain  
 anatomy of, 443  
 stem, functions of, 23  
 waves  
 classification of, 275  
 frequency and amplitude of, 275
- Breath control. *See* Respiratory patterns
- Breathing techniques *See also* Respiratory  
 patterns; Voluntary control  
 during meditation, 229  
 during neuromuscular relaxation, 229
- Brief reactive psychosis, 93, 95
- Brown, B., 270
- Bruxism, 272, 280
- Buddhist, 202, 203
- Budzynski, T., 108, 109
- Bulimia, pharmacological  
 therapy for, 300, 377
- Buspirone (BuSpar®), 325–326
- C**
- Caffeine, 8, 27, 92, 357, 358, 371, 374, 378
- Caffeine adverse effects of  
 intoxication, 358  
 soft drink content of, 357  
 as stimulant, 358  
 stress response-inducing activity of, 8, 92
- Cancer *See also* Specific types of cancer  
 chemotherapy, neuromuscular relaxation  
 use with, 240  
 disability-adjusted life years associated  
 with, 4  
 exercise as preventive and treatment  
 for, 336, 339  
 meditation as adjunct treatment for, 210  
 oxidative stress-related, 354  
 patients, quality-of-life of, effect of  
 religion on, 90, 210, 386
- Cannon, W., 427
- Carbamazepine, 416
- Carbohydrates, 348–351, 353, 360, 378
- Carbon dioxide sensitivity, meditation-related  
 decrease in, 208
- Cardiac output, during stress response and  
 exercise, 34, 110, 297, 298
- Cardiopulmonary fitness, exercise guidelines  
 for, 339
- Cardiopulmonary system, effect of exercise  
 on, 339
- Cardiorespiratory training, 304–307
- Cardiovascular disease  
 disability-adjusted life years  
 associated with  
 coronary artery disease, 75–76, 178  
 disability-adjusted life years in, 91  
 essential hypertension, 71, 74, 94, 178  
 myocardial ischemia, 75–76, 94  
 oxidative stress-related, 75  
 stress-related, 75  
 vasospastic phenomena, 75, 94  
 patients, effect of prayer on, 91
- Cardiovascular measurement, of the stress  
 response, 109–110
- Cardiovascular oxidative stress-related, 75

- Cardiovascular system effect of exercise on, 41, 71–74, 94, 279, 297  
physiology of, 72–73
- Carotenoids anticarcinogenic activity of, 354  
antioxidant activity of, 354
- Cataracts, oxidative stress-related, 354
- Catecholamine-*O*-methyl-transferase (COMT), 111
- Catecholamines type A behavior-related release of, 130
- Catecholaminogenesis, 33
- Catechols, 33
- Caudill, M., 173, 189
- CD4 cells, 89, 90
- CD-RISC. *See* Connor Davidson Resilience Measure (CD-RISC)
- Celexa (citalopram), 323, 324
- Centers for Disease Control and Prevention (CDC),
- Central nervous system  
anatomy and function of  
animal studies of, 83–84  
human studies of, 84–85  
interaction with immune system, 84–85  
role in stress response, 91–93  
depressants, pharmacology of, 319, 321, 328
- Cervical cancer, 272
- CGQ. *See* Common Grief Responses Questionnaire (CGQ)
- Challenger Space Shuttle, 375
- Chanting, as meditative practice, 203
- Charging, neurological, 180–181
- Chemotherapy, anticipatory nausea and vomiting associated with, 240
- Chernobyl, 375, 379
- Childbirth, natural, 224
- Children, trauma exposure in, 226, 419
- Chloral hydrate, 320
- Chlordiazepoxide (Librium®), 319, 320
- Chloride absorption and excretion of, 36  
role in neural transmission, 19
- Chlorpromazine (thorazine), 326
- Cholesterol levels, effect of aerobic exercise on, 302
- Cholinergic sympathetic response, 25
- Chromaffin cells, 33
- Chromatography, high-pressure liquid (HPLC), 111
- Chronic fatigue syndrome, 302
- Cingulate cortex, role in emotional arousal, 175
- Cingulate gyrus anatomy of  
cognitive appraisal function of, 28  
role in emotional arousal, 176
- Circadian rhythms, 371, 373, 374, 379
- Circadian rhythm sleep disorder, 373, 374, 379
- CISM. *See* Critical incident stress management (CISM/CSIM)
- Citalopram (Celexa®), 323, 324
- Classical conditioning of the autonomic nervous system, 269
- Clomipramine (Anafranil®), 323, 324
- Clonazepam, 320, 416
- Clonidine, 416
- Clorazepate (Tranxene®), 319, 320
- Clozapine (Clozaril®), 326
- Cocanut Grove Night Club, 386
- Cognitive-affective correlate scales, 106
- Cognitive-affective domain, of the stress Response, 28–30, 41, 44, 45
- Cognitive appraisal, 7, 27, 28, 30, 144, 159
- Cognitive-behavioral therapy  
hypnosis use with, 258, 264, 317, 418  
spirituality-focused, 304
- Cognitive-Behavior Modification* (Meichenbaum), 163, 164
- Cognitive deficits, posttraumatic stress disorder-related, 351
- Cognitive diffusion, 169
- Cognitive distortion, 127, 128, 132, 139, 159, 161, 162, 188
- Cognitive interpretation, of stressors, 157, 448
- Cognitively-based, 151, 157, 158, 160, 163
- Cognitive primacy theory, 158–160, 168
- Cognitive restructuring, 157, 161–163, 168, 228, 258, 261, 279, 281, 335, 449
- Cognitive therapy Beck's model of, 161–163, 168  
origin of, 161 (*see also* Cognitively-based; Psychotherapy)
- Cold exposure, stimulant effects of, 75
- College de France, 441
- Colon cancer  
exercise as preventive and treatment for, 299, 302  
sedentary lifestyle as risk factor for, 302
- Combat fatigue, 256
- Committed action, 167
- Common Grief Responses Questionnaire (CGQ), 117
- Communication, ideomotor, 257
- Complement system, 82
- Complex carbohydrates, 348, 360
- Complicated grief, 119, 337, 385, 388–390
- Compulsive disorders, pharmacological therapy for, 119
- Compulsive personality, 135
- COMT. *See* Catecholamine-*O*-methyl-transferase (COMT)

- Concanavalin A (ConA), 82, 85, 88  
 Conditioning and Learning (Kimble), 269  
 Conflict theory  
   of characterological conflicts, 128  
   of psychosomatic disease, 58, 62  
 Connor Davidson Resilience Measure (CD-RISC), 119  
 Constructionist therapy, 393  
 Conversion hysteria, 10, 114  
 Cooper, K., 240, 295  
 Cooper 12-Minute Test, 303  
 Coping  
   active and passive styles of, 34, 37, 84  
   adaptive, 44, 168  
   anticipatory, 44  
   assessment of, 121  
   definition of, 44  
   maladaptive, 7, 29, 44  
   passive, 37, 84  
   strategies  
     religion, 336  
     self-report checklist for, 165  
 Corgard® (nadolol), 327  
 Cornell University, 238  
 Coronary artery  
   bypass patients, recovery in, effect of perceived control on, 338  
   disease  
     meditation treatment for, 210  
     myocardial ischemia associated with, 75–76  
     relationship with type A behavior, 129, 130  
 Corticosteroids, effect on immune function, 111  
 Corticosterone, 35, 83  
 Corticotropin-releasing factor (CRF), 35, 37, 411  
   in posttraumatic stress disorder, 37  
 Cortisol  
   measurement of, 123, 239  
   type A behavior-related release of, 130  
 Costa, P., 129  
 Cousins, N., 90, 94  
 Creatine, 305  
 CRF. *See* Corticotropin-releasing factor (CRF)  
 Crisis, 331, 402, 427–434  
 Crisis intervention, 331, 427–434  
 Critical Incident Stress Management (CISM/CSIM), 430, 431  
 Culture of resilience, 150–152  
 Curare, 269  
 Curcumin, 347  
 Cushing, H., 443  
 Cushing's syndrome, 36  
 Cybex, 295  
 Cytokines, 80, 81, 86–89  
 Cytolysis, 82  
  
**D**  
 Dalmane® (flurazepam), 321  
 Death, 3–5, 34, 41, 54, 62, 67, 75, 117, 131, 147, 178, 238, 293, 294, 301, 302, 336, 358, 373, 385, 386, 388–395, 402, 403, 406, 407, 440  
   Death, premature, 4, 293  
   diaphragmatic breathing, 261  
 Deep sleep, 275, 470  
 de Jussieu, L., 255  
 Delta sleep, 370  
 Dembroski, T., 129  
 Dendrites, 18  
 Deoxycorticosterone, 36  
 Dependence, self-induced, 58, 116, 136, 319–321, 326, 328, 338, 429  
 Dependent personality, 136  
 Depersonalization, relaxation training-related, 190, 193, 321, 407  
 Dephenhydramine (Benadryl®), 327  
 Depression  
   in Alzheimer's disease caregivers, 89–90  
   anterior-pituitary-adrenocortical axes in, 92  
   as disorder of arousal, 60  
   dopamine deficiency associated with, 86  
   effect of exercise on, 300  
   effect of religious beliefs on, 336, 337  
   gastrointestinal response to, 37  
   in human immunodeficiency virus-positive individuals, 89  
   norepinephrine deficiency associated with, 86  
   serotonin deficiency-related, 86  
 Derogatis Stress Scale, 122  
 Desensitization neurological  
   as phobia treatment, 238  
   as posttraumatic stress disorder treatment, 418  
   systematic, 238, 258, 278  
   use with hypnosis, 258, 259, 418  
 Desipramine (Norpramin®), 323, 324  
 Deutsch, F., 9

- Diabetes mellitus, neuromuscular relaxation treatment for, 240
- Diabetics, biofeedback use by, 280
- Diagnosis, of the stress response  
 physical, 113  
 psychological, 113–114
- Diagnostic and Statistical Manual of Mental Disorders*  
 Multiaxial, 10  
 posttraumatic stress disorder diagnostic criteria of, 93
- Diagnostic and Statistical Manual of Mental Disorders-II (DSM-II)*, 9
- Diagnostic and Statistical Manual of Mental Disorders-III (DSM-III)*, 176, 401, 404
- Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV)*, 4, 10, 106, 116, 119, 120, 176, 373, 388, 402–404, 406, 407, 415
- Diagnostic and Statistical Manual of Mental Disorders-III-R (DSM-III-R)*, 176
- Diaphragmatic breathing, 225–228, 232, 277, 279, 280  
 precautions in use of, 227
- Diathesis-stress model, 56
- Diazepam (Valium®), 319, 320
- Disability-adjusted life year (DALY), 4
- Disease  
 mediating mechanisms of, 318  
 psychosocial factors in, 53
- Disorders of arousal model, of, 59, 60, 62, 411  
 psychosomatic disease, 59
- Disregulation model, of psychosomatic disease, 57–58
- Dissociation, 144, 257
- Distraction imagery, 261
- Distress, 7, 11, 37, 87, 89, 119, 135, 143–145, 160, 161, 166–169, 209, 299, 336, 352, 372, 373, 375–377, 385–390, 392, 393, 403–407, 409, 413, 427–430, 432–434, 441
- Diuresis, psychosocial stimuli-induced, 39
- Divorce, effect on immune function, 87
- DNA (deoxyribonucleic acid), oxidative stress-related damage to, 355
- Domar, A., 173, 189
- Dopamine (DA)  
 deficiency of, as depression cause, 318  
 drug interactions of, 321  
 neuronal pathways of, 321  
 in posttraumatic stress disorders, 325  
 in schizophrenia, 318
- Doriden® (glutethimide), 328
- Doxepin (Sinequan®), 324
- Dreaming, 369, 375, 376, 379
- Drug abuse  
 meditation treatment for, 210
- Drug reactions, relaxation training-related, 191
- Drug therapy. *See* Pharmacological therapy
- Duchesne, J., 295
- Duke University Medical Center, 337
- Dunbar, H.F., 7, 127, 128, 138
- Duodenal ulcers, 68, 69
- Duodenum, anatomy and physiology of, 68
- Dynamic muscular tension, 238
- E**
- Eczema, 78, 94
- Efferent autonomic pathways, 24
- Effexor® (venlafaxine), 325
- Ehrmann, M., 447
- Einstein, A., 333
- Elavil® (amitriptyline), 324
- Electrocardiography, 19
- Electrodermal (EDR) biofeedback, 277–278
- Electrodermal measures, of the stress response, 107–108
- Electroencephalographic (EEG) biofeedback, 275–277
- Electroencephalography (EEG)  
 effect of “healing energy” on, 340  
 during meditation, 206
- Electromyographic (EMG) biofeedback, 271–273
- Electromyographic measures, of the stress response, 108–109
- Eliot, R., 74, 178
- Ellis, A., 7, 12, 28, 160, 161, 168, 257, 335, 341
- EMDR. *See* Eye movement desensitization and reprocessing (EMDR) therapy
- Encyclopedia of Endocrinology* (Selye), 342
- Endocrine axes, in stress response, 34, 35, 40, 107, 111–112  
 assessment of, 111–112
- Endorphins, 35, 298, 309
- Energy drinks, 331, 357–358, 361
- Engel, G., 445
- Engram model, of memory, 183
- Enlightenment, 201, 206
- “Environmental engineering,” 163, 166, 168, 449, 450,

Epictetus, 7, 28, 157  
 Epilepsy, biofeedback treatment for, 280  
 Epinephrine as arrhythmia cause  
   interaction with adrenocorticotrophic hormone, 36  
   measurement of, 110  
   secretion of, 33  
   stress-related release of, 297  
 Epstein–Barr virus, 88  
 Equanil (meprobamate), 328  
 Ergotropic response, 32, 298  
   exercise-related, 298  
 Ergotropic tuning phenomenon, 130  
   type A behavior-related, 130  
 Erickson, M.H., 256  
 Esophagitis, 71  
 Esophagus, anatomy and physiology of, 68  
 Estazolam (ProSom®)  
 Ethchlorvynol (Placidyl®), 328  
 Eustress, 11  
 Everly, G.S., 5, 7, 9, 12, 27, 28, 30, 42, 44, 59–61, 69, 73, 92–94, 103, 106–109, 112, 121–123, 128–130, 132–134, 136, 138, 144, 145, 147, 150, 151, 163, 166, 177, 185, 189, 190, 192, 193, 230, 273, 301, 402, 408, 409, 411–414, 417, 420, 421, 429, 430, 432, 449, 450  
 Exercise  
   equipment, 295  
   therapeutic, 155, 294–296  
     aerobic, 90  
     anaerobic, 307  
     FITT prescription guidelines for, 303  
     for general health improvement, 307  
     guidelines for, 303–304  
     history of, 294–296  
     as panic attack cause, 299  
     research in, 296  
     for stress management action  
       mechanisms of, 299  
     tolerance testing, 303  
 Expert Consensus Panel for the Treatment of Posttraumatic Stress Disorder, 416  
 Exxon Valdez, 374, 379  
 Eye movement desensitization and reprocessing (EMDR) therapy, 417–420  
**F**  
 Facial muscles, neuromuscular relaxation of, 251  
 “Faith factor,” 334, 342  
 Family Disruption from Illness Scale, 113

Fat  
   dietary, 357, 359  
   stress-associated consumption of, 350  
 Fatigue, relaxation response-related, 192  
 FFA. *See* Free fatty acids (FFA)  
 Fibromyalgia, meditation treatment for, 276  
 Fight-or-flight response, 32–34, 47, 77, 271, 410  
 Fitness, as stress buffer, 301  
 Fixx, J.F., 295  
 Flashbacks, posttraumatic stress disorder-related, 410  
 Flexibility exercise, 306  
 Fluid intake, during stress, 351  
 Fluoxetine (Prozac®), 324  
 Flurazepam (Dalmane®), 319  
 Fluvoxamine (Luvox®), 324  
 Focused imagery, 261  
 Folkman, S., 7, 28, 44, 121, 123, 131, 188  
 Food *See also* Nutrition  
   low-energy, 352  
 Forgiveness, 334, 335, 341, 342  
 Forgiveness-based interventions, 341  
 Fornix, role in emotional arousal, 175  
 Frank, E., 389  
 Franklin, B.A., 256  
 Free fatty acids (FFA), 34, 36, 38, 293, 297, 309  
 Free radicals, 354, 355, 361  
 Freud, S., 256, 401  
 Friedman, M., 58, 128, 129, 131, 417  
 Frontalis muscles as electromyographic biofeedback electrode site  
   as electromyographic measurement site, 108  
   relaxation of, 272  
   in stress response, 272  
 Frontal lobe, 23, 205  
 Fruit, carotenoid-containing, 347, 348, 352, 355, 356, 360  
**G**  
 GABA. *See* Gamma-aminobutyric acid (GABA)  
 Gallbladder, function of, 68  
 Galvanic skin response, 107, 208, 277  
 Galvani, L., 277  
 Gamblers Anonymous, 341, 342  
 Gamma-aminobutyric acid (GABA), 19, 318, 320  
 Gamma motor system, 298  
 Gastric ulcers, 68, 69  
 Gastroesophageal reflux, 71  
 Gastrointestinal disorders, stress-related  
   esophagitis, 71  
   gastroesophageal reflux, 71

- irritable bowel syndrome, 67, 70–71, 93
  - peptic ulcers, 67–70
  - ulcerative colitis, 67, 70
  - Gastrointestinal tract, physiology of, 36
  - Gellhorn, E., 9, 28–30, 32, 59, 92, 94, 108, 130, 174, 176–182, 185–188, 208, 237–239, 298, 411
  - General adaptation syndrome (GAS), 39–41, 47, 54–55, 62, 69, 83, 94, 440
  - Generalized anxiety disorder, pharmacological therapy for, 326
  - Generalized Anxiety Disorder Questionnaire (GADQ-IV), 119
  - General Nutrition Center (GNC), 296
  - German Medical School, Prague, 438
  - Germ theory, of disease, 3
  - Gingko biloba 7, 25, 27, 403
  - Ginseng, 7, 27, 357
  - Global Burden of Disease Study, 4
  - Globulins, 81
  - Glucocorticoid hormones
    - release of, 36
  - Glucose, 25, 36, 38, 293, 301, 306, 348, 351, 353
  - Glutamate, in posttraumatic stress disorder, 409
  - Glutethimide (Doriden®), 328
  - Glutethimide ethchorvynol, 320
  - GNC. *See* General Nutrition Center (GNC)
  - God, belief in, 334
  - Greeks, ancient, 294
  - Grief, 7, 85, 89, 117, 119, 331, 336, 337, 385–396
    - in children, 331, 394
  - Group therapy,
    - for posttraumatic stress disorder, 417
  - Growth hormone, 37, 38, 41, 444
  - Gruzelier, J.H., 257, 263
  - Guarana, 7, 27, 357
  - Guided imagery, 89, 90, 212, 226
  - “Gut reactions,” 29
- H**
- Halcion (triazolam®), 319
  - Haloperidol (Haldol), 326
  - Hammer Strength® (exercise equipment), 295
  - Handbook of Hypnotic Suggestions and Metaphors* (Hammond, ed.), 259
  - Hardiness, 130, 131, 144, 149–150, 152
  - Harvard Step Test, 303
  - Harvard University, 59, 243
  - Hassles Scale, 105, 121–123
  - Hatha yoga, 203, 223
  - Hay fever, 76
  - Headaches
    - electromyographic biofeedback treatment for, 261, 272
    - migraine, 12, 58, 71, 75, 94, 132, 178, 270, 274, 276
    - muscle tension, 190, 272
    - pathogenic arousal-related, 178
    - relaxation training-related, 270
  - Health behavior, effect of religion on, 3–5
  - Health, positive effects of stress on, 335
  - Health-related behavior, 3
  - Healthy People* (U.S. Public Health Service), 4
  - Heart
    - anatomy and function of, 25
    - attack risk, effect of religious beliefs on, 444
    - disease (*see* Cardiovascular disease)rate measurement of, 109
      - meditation-related decrease in, 208
      - in stress response, 109
    - surgery patients, mortality rate,
      - effect of religious beliefs on, 338
  - Helplessness/hopelessness depression syndrome, 36, 37, 189, 391, 404, 406, 407, 416
  - Hemorrhage, hypnosis-related control of, 260
  - Hepatitis vaccination, 88
  - Herbs
    - with antianxiety properties, 356
  - Herodicus, 294, 309
  - Herpes viruses, antibodies to, 82
  - “Highway hypnosis,” 208
  - Hindu, 202, 203, 207, 223, 224
  - Hippocampus
    - anatomy of, 408
    - neurological triggering function of, 30
    - role in emotional arousal, 175
  - Hippocrates, 439
  - Histamine, 68, 79
  - Histrionic personality, 135
  - Hitchcock, E., 295
  - Holmes-Rahe Social Readjustment Scale, 88
  - Holmes, T., 105
  - Homeostasis
    - in anxiety, 181, 182
    - disregulation of, 57
    - failure of, 52–53, 62
    - regulation of, 23, 58
  - Hooke’s Law, 6, 441
  - Hospitals, “Laugh Mobiles” in, 90
  - Hostility gastrointestinal response to, 71
    - type A behavior-related, 58
  - Howard, J.E., 445

- HPAC. *See* Hypothalamic-pituitary-adrenal-cortical system (HPAC)
- HPLC. *See* Chromatography, high-pressure liquid (HPLC)
- Hull, C.L., 256
- Human immunodeficiency virus (HIV)  
infection  
immune dysfunction associated with, 89  
neuromuscular relaxation adjunct treatment for, 89  
positive persons, 89  
exercise by, 89, 90
- Humor, effect on immune function, 83, 90, 94
- Humor Research Task Force, 90
- Hunger, differentiated from appetite, 352, 361
- Hunter, J., 67
- Hurricane Andrew, 91
- 17-Hydroxycorticosteroid, 112
- Hydroxyzine (Atarax<sup>®</sup>; Vistaril), 327
- Hyperadrenocorticism, 36
- Hyperalertness, *Diagnostic and Statistical Manual of Mental Disorders*, 176  
*classification of*, 174
- Hypermnesia, 257, 263
- Hypersensitivity  
*Diagnostic and Statistical Manual of Mental Disorders classification of*, 176  
neurological, 59, 174, 179–186, 189, 409–412, 417, 418, 420  
neuronal plasticity in, 182, 184  
posttraumatic stress disorder-related, 417  
psychological, posttraumatic stress disorder-related, 412–413, 417  
to stimulation, 175, 179, 181
- Hyperstartle response, 416
- Hypertension  
definition of, 74  
electrodermal biofeedback treatment for, 278  
essential, 71, 74, 94, 109, 166, 178, 210  
meditation treatment for, 210  
neuromuscular relaxation treatment for, 189  
personality characteristics associated with, 74  
secondary, 74
- Hyperventilation, 77, 94, 226–230, 232
- Hypnosis  
action mechanisms of, 263  
history of, 255–256  
induction of, 258,  
as psychotherapy adjunct, 256, 258  
for specific stressors, 264  
as stress management technique  
comparison with other stress reduction, 255–264  
in surgical patients, 256, 260  
techniques, 258–259, 261, 263, 264  
theories of, 257
- Hypnotizability, 262, 263
- Hypoarousal relaxation response, 59
- Hypocapnia, 227
- Hypoglycemia controlled breathing-related relaxation response-related, 1927
- Hypokinetic diseases, 56–57, 62, 294, 309
- Hypokinetic model, of psychosomatic disease, 62
- Hypophysectomy, 442
- Hypotension controlled breathing-related relaxation response-related, 192
- Hypothalamic-pituitary-adrenal axis, in posttraumatic stress disorder, 411–412
- Hypothalamic-pituitary-adrenal-cortical system (HPAC), 36–37, 47
- Hypothalamus anatomy of  
neurological triggering function of, 27  
posterior, effect of neuromuscular proprioceptive feedback on, 31, 237  
role in emotional arousal, 32  
role in stress response, 32
- Hypothyroidism, 38
- I**
- Ideation, repressed, relaxation training-related freeing of, 190, 191, 193
- Ideomotor communication, 257
- Iliad* (Homer), 4
- Illness, 4, 5, 28, 29, 53, 54, 56, 58, 62, 63, 85, 87, 89, 91, 92, 105, 106, 113, 123, 131, 132, 150–152, 177, 183, 255, 318, 335, 336, 354, 387, 438, 441, 446  
multifactorial etiology of, 3
- Imipramine (Tofranil<sup>®</sup>), 322
- Immune system  
functional assessment of, 84–89  
relationship with central nervous system, 86
- Immunity acquired  
cell-mediated, 80  
humoral-mediated, 80  
innate, 78–80
- Immunoglobulins, 81
- Immunosuppression, stress-induced.  
*See* Psychoneuroimmunology
- Impact of Events Scale-Revised (IES-R), 117, 123

Inderal® (propranolol), 327  
 Infectious disease disability-adjusted life years  
   associated with, 4  
   effect of environmental stress on, 83  
 Infertility, hypnosis as treatment for, 260  
 Ingle, D., 445  
 Initial values, law of, 121  
 Insomnia, 92, 321, 323, 326, 327, 358, 372,  
   374, 377, 378  
 Institute of Experimental Medicine and  
   Surgery, 439  
 Institute of Medicine, Food and Nutrition  
   Board of, 355  
 Insulin therapy, 38, 191, 192, 240,  
   280, 299, 353  
 Interferon, 79, 86  
 Interleukin-1, 80  
 Interleukin-2, 80  
 International Society for Neurofeedback  
   and Research (ISNR), 283  
 Interoceptive exposure (IE), 228  
 Interstitial cell-stimulating hormone, 39  
 Intestines, anatomy and physiology of, 68  
 Inventory of Complicated Grief Scale, 119  
 Inventory of Psychosocial Functioning, 120  
 Irritable bowel syndrome, 67, 70–71, 93, 178  
 ISNR. *See* International Society for  
   Neurofeedback and Research  
   (ISNR)

## J

Jacobson, E., 92, 94, 108, 109, 237–240, 250,  
   251, 261, 269, 298, 431  
 James, W., 238  
 Janet, P., 256  
 Jogging, 203, 299, 304, 307  
 Johns Hopkins Model  
   of PFA, 145  
   of resilience, 145, 151  
 Johns Hopkins Precursors Study, 131  
 Johns Hopkins University, 438  
*Journal of Clinical Psychiatry*, 416  
*Journal of Evidence-based Complementary  
   and Alternative Medicine*, 283  
*Journal of Health*, 295  
*Journal of Neurotherapy*, 283  
 “Just being sick” syndrome, 6, 33, 439, 441

## K

Kennedy, J.F., 294, 295  
 Kimble, G.A., 269  
 Kindling phenomenon, 183, 184  
 Klinefelter, H., 445

Knee-jerk reflex, 238  
*Koan*, 204  
 Kobasa, S., 130, 145, 149, 152  
 Korotkoff sounds, 110  
 Kraus and Raab’s hypokinetic model, of  
   psychosomatic disease, 56–57, 62  
 Kübler-Ross, E., 386, 387, 396  
   acceptance, 386  
   anger, 386  
   bargaining, 386  
   denial, 386  
   depression, 386  
 Kung Fu, 224  
 Kutz, I., 173, 188, 189, 210

## L

Lachman’s behavioral model, of  
   psychosomatic disease, 55  
 Lactic acid, anxiogenic property of, 182  
 Lafayette, de, Marie Joseph (Marquis), 256  
 Large intestine, anatomy and physiology of, 68  
 Law of Initial Values, 121  
 Lazarus, R.S., 7, 12, 28, 29, 44, 85, 105, 121,  
   123, 131, 159, 160, 188, 258  
 Legumes, 347–349, 360  
 Librium® (chlordiazepoxide), 319, 320  
 “Lie detection” equipment, 278  
 Life Events and Difficulties Schedule  
   (LEDS), 58  
 Life Experiences Survey (LES), 105, 122  
 Life Stressor Checklist-Revised, 106  
 Limbic hypersensitivity  
   ergotropic tuning, 179–180  
   etiological and/or sustaining mechanisms  
     of, 185  
   neurological foundations of, 179–182  
   neurological reverberations and charging,  
     180–181  
   neuromuscular set-point, 181–182  
 Limbic system anatomy of  
   cognitive appraisal function of, 27, 30  
   components of, 23  
   emotional arousal function of, 30, 32,  
     175, 176  
   neurological triggering function of,  
     27, 30–31, 107, 123, 448  
   relaxation response-induced neurological  
     desensitization of, 187–189  
   role in emotional arousal, 30, 32,  
     62, 175, 176  
   role in stress response, 23  
 Lindemann, E., 386, 396  
 Lipid-lowering drugs, 339  
 Lithium, 416

- Locus ceruleus, 19, 27, 30, 45, 318, 410  
 Locus of control, internal and external, 134  
 Logic, faulty, 162  
 Lopressor® (metoprolol), 327  
 Lorazepam (Ativan®), 319, 320  
 Low back pain, 77  
 Low-density lipoprotein (LDL)  
   cholesterol, 297  
 Lung cancer, 4, 85  
 Luteinizing hormone, 39  
 Luvox® (fluvoxamine), 323, 324  
 Lyme disease, 277  
 Lymphatic system, 80  
 Lymph nodes, 80, 81  
 Lymphocytes, 79–83, 85, 90, 91  
 Lymphotoxin, 81  
 Lysozyme, 70
- M**
- MacLean, P.D., 22, 30, 175, 176, 407  
 Macrophages, 79–81  
 Macular degeneration, oxidative  
   stress-related, 354  
 Magnetic illness, 255  
 Maharishi Mahesh Yogi, 202  
 Major depressive disorder, pharmacological  
   therapy for, 323, 337, 388  
 Mammillary bodies, role in emotional  
   arousal, 175  
*Mandala*, 204  
 Mania, 92  
 McCabe, P., 34, 36, 297  
 McGill University, 439  
 Meditation  
   action mechanisms of, 204–207  
   clinical applications of, 209–210  
   clinical implementation of, 211–216  
   continuum of, 209, 212, 213  
   contraindications to, 211  
   definition of, 201  
   effectiveness of, 209–210  
   focal devices in, 203  
   history of, 201–202  
   by nursing-home residents, 260, 263  
   research on, 209–210  
   strategic, 209  
   therapeutic hallmarks of, 207–209  
   types of, 202–204  
 Mediterranean diet, 256, 347, 350, 361  
 Melatonin, 371, 374  
 Mellaril (thioridazine), 326  
 Memory B cells, 82  
 Memory, engram model of, 184  
 Menstrual cycle, panic attacks during, 132,  
   158, 182, 258, 299, 317, 320, 322,  
   324, 408  
 Mental illness, as morbidity and mortality  
   cause, 4, 5, 131, 151, 318  
 Meprobamate (Equanil; Miltown®),  
   320, 328  
 Mesmer, F.A., 255, 256, 263  
 Mesmerism, 255, 256  
 Mesoridazine (Serentil), 326  
 Metanephrines, measurement of, 111  
 Methylated xanthines, 92  
 Metoprolol (Lopressor®), 327  
 Millon Behavioral Health Inventory, 122  
 Millon Clinical Multiaxial Inventory  
   (MCMI), 115, 123, 414,  
   415, 421, 449  
 Millon Clinical Multiaxial Inventory-II  
   (MCMI-II), 115, 116  
 Millon Clinical Multiaxial Inventory-III  
   (MCMI-III), 115, 116, 416  
 Millon, T., 2, 28, 93, 115, 122, 128, 132–134,  
   136, 138, 139, 189, 451  
 Miltown (meprobamate), 328  
 Mind-body interaction, 449  
 Mineralocorticoids, 36, 38  
 Minerals, nutritional role of,  
   295, 302, 348, 352  
 Minnesota Multiphasic Personality  
   Inventory-2 (MMPI-2), 114  
 Mirtazapine (Remeron®), 323, 325, 416  
 Mitogens, 82, 85, 87  
 Moderate-intensity exercise, 304, 309,  
 Moll, A., 256  
 Monoamine neurotransmitter  
   theory, of exercise, 298  
 Monoamine oxidase inhibitors (MAOIs),  
   322, 416  
 Monocytes, 79, 82  
 Mood disorders  
   affective symptom complexes of, 174  
   prevalence of, 4  
 Mount Athos, Greece, 202  
 Mourning, 385–387, 395, 396  
 Multiple Affect Adjective Checklist  
   (MAACL), 118, 119  
 Muscle confusion, 296  
 Muscle contraction, release of, in, 178, 271,  
   272, 370  
   neuromuscular relaxation, 178  
 Muscle relaxation, exercise-induced, 298  
 Muscle strain, differentiated from muscle  
   tension, 241, 251  
 Muscle strengthening, 307

- Muscle tension in anxiety states  
differentiated from muscle strain, 251  
electromyographic biofeedback  
control of, 271–273  
exercise-related control of, 193, 238
- Musculature, stress-related activation of,  
23, 45, 108, 109, 179, 298
- Musculoskeletal disorders, stress-related,  
77–78
- Musculoskeletal system, operant conditioning  
of, 269
- Music listening, effectiveness of, 261
- Myocardial infarction, meditation treatment  
for, 210
- Myocardial ischemia, 34, 75–76, 94, 299
- N**
- Nadolol (Corgard®), 327
- Narcissistic personality, 135
- Narcolepsy, 371
- Narcotics Anonymous, 341, 342
- Nardil® (phenelzine), 322, 323
- National Center for Complementary  
and Alternative Medicine  
(NCCAM), 202
- National Health Fair, 121
- National Sleep Foundation, 371, 372, 375, 377
- Natural disasters, 396
- Natural killer (NK) cells, 79  
trauma-related decrease in, 90–91
- Nautilus exercise equipment, 295
- Navane (thiothixene), 326
- Nefazodone (Serzone®), 323, 325, 416
- Neocortex, 22, 23, 29, 180, 182, 204
- Neural axes, 31–32, 107
- Neural cell bodies, 18
- Neural transmission, 18–21
- Neuroanatomy, of the stress response, 21, 410
- Neurobiology, of the stress response  
neural transmission, 18–21  
neuroanatomy, 21–24
- Neurocognitive strategic therapy, for  
posttraumatic stress disorder,  
417–418
- Neuroendocrine axis, 31, 33–40, 47, 107,  
110–111  
assessment of, 110–111
- Neurohypophysis, 38
- Neuromotor exercise training, 306
- Neuromuscular relaxation  
action mechanism of, 239–240  
definition of, 237  
history of, 237–239  
implementation of, 241  
as mental imagery technique, 250  
physically-active, 241  
physically-passive, 252  
preparation phase, 241  
procedure, 242–250  
protocol, 242–250
- Neuromuscular set-point theory, 181–182
- Neuronal plasticity, 182–186
- Neurons  
anatomy and function of, 18  
polarization/depolarization/ repolarization  
of, 181  
role in stress response, 9, 21, 23, 29, 108,  
318, 410
- Neurotransmitters, 18, 19, 86, 177, 185, 318,  
319, 322, 411  
effect of psychotropic drugs on, 318, 319
- Neutrophils, 79, 82, 91
- New Testament, 4
- New York Academy of Medicine, 445
- Nicotine, 27, 177
- Nirvana, 206, 208
- Noise, vasoactive response to, 448
- Non-REM (NREM) sleep, 370
- Noradrenaline. *See* Norepinephrine
- Noradrenergic sympathetic innervation,  
of immune system organs, 375
- Norepinephrine  
antidepressant-associated increase in, 321  
deficiency of, as depression cause, 318  
drug interactions of, 319, 322  
exercise-associated release of, 47  
interaction with adrenocorticotrophic  
hormone, 35  
interaction with serotonin, 86,  
318, 321, 416  
measurement of, 109, 110  
neuronal pathways of, 19  
in relaxation response, 187, 318  
stress-related release of, 109  
synthesis of, 36  
target-organ effects of, 111, 112  
vasoconstrictive effects of, 109
- Norpramin® (desipramine), 323, 324
- North Ridge earthquake, California, 91
- Northwestern University, 238
- Nortriptyline (Pamelor®), 323, 324
- Nutrigenomics, 359, 361
- Nutrition  
antioxidants, 354–357  
energy sources during stress, 351–352  
energy-yielding nutrients, 348  
psychoneuronutritional medicine and, 348  
serotonin, 353
- Nutritional supplements, 359

**O**

- OA. *See* Osteoarthritis (OA)
- Obama, B., 294
- Obama, M., 294
- Obesity, hypnosis/cognitive-behavioral therapy for, 258, 264
- Observation, detached, 207, 208
- Obsessive-compulsive disorder, pharmacological therapy for, 120, 317, 323, 324
- Oklahoma City bombing, 392
- Olanzapine (Zyprexa®), 326
- Operant conditioning
  - of the autonomic nervous system, 269
  - of the musculoskeletal system, 269
- Opioids, endogenous, 34, 35, 298, 411
  - in posttraumatic stress disorder, 411
- Optimal stress level, 11
- Oral cavity cancer, 260, 320
- Oscillometry, 110
- Osler, W., 3, 127
- Osteoarthritis, 4, 300
- Osteoarthritis (OA), 4, 300
- Overeating, 352
- Over-the-counter drugs, caffeine content of, 92, 357–358, 371
- Oxazepam (Serax®), 319, 320
- Oxidative stress, 354, 355, 359, 361
- Oxygen consumption, during meditation, 207, 370
- Oxytocin, 38, 39, 411

**P**

- Pain management with hypnosis, 256
  - with meditation, 208
- Pallares, S., 444
- Pamelor® (Nortriptyline), 324
- Panic attacks etiology of
  - pharmacological therapy for, 317
  - prevalence of, 401
  - rational stage directed hypnotherapy (RSDH) for, 258
- Panic disorder
  - with agoraphobia, 227
  - controlled breathing treatment for, 227
  - lactate metabolism in, 182
  - personality traits associated with, 132
- Panic states, relaxation training-related, 191
- “Papez Circuit,” 176
- Parasympathetic nervous system
  - anatomy and function of, 31, 32
  - end-organ effects of, 32
  - neural activation function, 32
- Parnate® (tranylcypromine), 322, 323
- Paroxetine (Paxil®), 323, 324
- Passive-aggressive personality, 136
- Passivity, 37, 136, 208
- Pasteur, L., 3, 53, 441
- Pavlov, I., 256, 269
- Paxil® (paroxetine), 323, 324
- Peer support, 417, 434
- Penn Inventory For Posttraumatic Stress Disorder (PENN), 117
- Pepsin, 68
- Pepsinogen, 69
- Peptic ulcers, 12, 67–70, 93, 178, 240
  - neuromuscular relaxation treatment for, 240
- Perceived Stress Scale (PSS), 205, 206
- Performance, positive effects of stress on, 349
- Peripheral blood flow resistance, during stress, 297
- Peripheral nervous system anatomy and function of, 318
  - in stress response, 318
- Personality disorders, limbic hypersensitivity associated with, 177
- Personality of colitis patients
  - definition of, 133
  - Millon’s theory of, 133
- Personal relationships, effect on immune function, 87–88
- Personologic diatheses, stress and historical perspective on, 255–256
  - personality theory of, 134–138
  - personologic psychotherapy for, 133–134
  - principle of personologic primacy of, 132
- Personologic primacy principle, 132, 133, 139
- Peterson Memory Paradigm, 414
- Peter the Apostle, 4
- PHA. *See* Phytohemagglutinin (PHA)
- Phagocytosis, 79, 81
- Pharmacological therapy, 317–322, 324–326, 328
- Pharmacological therapy, for stress *See also* names of *specific* drugs
  - pharmacology of, 318–319
  - antidepressant, 321–322
  - benzodiazepin, 319–321
  - monoamine, 322
  - oxidase inhibit, 322
  - selective serotonin reuptake inhibitors, 324–325
  - tricyclic antidepressants, 322–324
- Phenelzine (Nardil®), 322, 323
- Phenylpropanolamine, 27
- Pheochromocytoma, 74
- Pheromones, 83

- Phobias  
 social, pharmacological treatment  
 for, 317, 323, 324  
 systematic desensitization  
 treatment for, 278
- Physical activity *See also* Exercise, therapeutic  
 in response to stress, suppression of,  
 293–299, 301, 302, 304, 307
- Physical exercise, 7, 144, 147, 155, 186,  
 293–310, 418, 450
- Physical inactivity, as disease risk  
 factor, 301, 302
- Phytohemagglutinin (PHA), 82, 85, 88
- P-I-E, 428
- Pilates, 296
- Pituitary gland anterior, endocrine function  
 of, 23  
 posterior, 38–39  
 role in hypothalamic functioning, 23
- Placebo effect, 334
- Placidyl (ethchlorvynol), 328
- Plasticity, neuronal, 182–186
- Plato, 294
- Plethysmography, 109
- Plyometric-style training, 296
- Pokeweed mitogen, 82
- Polyunsaturated fats, 350
- Positive psychology, 151, 152, 341
- Posthypnotic response, 257, 263
- Posttraumatic stress disorder  
 adrenal cortical response axis in, 35–37  
 adrenal medullary catecholamine axis in, 33  
*Diagnostic and Statistical Manual  
 of Mental Disorders classification  
 of*, 401, 404, 405  
 diagnostic symptomatology of, 402–408  
 exposure therapy, 419  
 historical reference to, 420  
 limbic hypersensitivity associated with, 177  
 locus ceruleus in, 410  
 misdiagnosis of, 421  
 natural killer cell cytotoxicity associated  
 with, 391  
 pharmacological therapy for, 415, 416  
 prevention of, 415–420  
 psychological hypersensitivity component,  
 409, 412–413, 417  
 psychological profile of, 413–415  
 treatment of, 415–420  
 two-factor theory of neurological  
 hypersensitivity component,  
 409–413  
 virtual reality, 419  
 war-related, 401
- Potassium, role in neural transmission, 19
- Pranayama, 203, 223, 233
- Prayer  
 intercessory, 339, 340,  
 as meditation, 202, 203
- Prefrontal cortex, cognitive appraisal  
 function of, 29
- Prefrontal lobe, 28
- Premature death, 4, 293
- President's Council on Physical Fitness, 295
- Prince, M., 256
- Problem solving, 23, 121, 143, 144, 148, 163,  
 165–168, 449
- Profile of Mood States (POMS), 118–119, 123
- Progressive relaxation  
 by human immunodeficiency virus-positive  
 individuals, 89  
 hypnoidal effects of, 263
- Prolactin, 39
- Prolonged grief  
 sorrow, 390  
 yearning, 389, 390
- Propranolol (Inderal®), 327
- Proprioceptive neuromuscular impulses  
 in ergotropic tuning, 179–180  
 learned awareness of, 239, 251
- ProSom® (estazolam), 319
- Protein, dietary, 351
- Prozac® (fluoxetine), 323, 324
- Psoriasis, 78, 94, 210
- PSS. *See* Perceived Stress Scale (PSS)
- Psychiatric/psychological disorders,  
 stress-related  
 as disorders of arousal, 175–177  
 personologic psychotherapy for, 133–134
- Psychoanalysis, 256, 263
- Psychological diagnosis, of the stress  
 response, 113–114
- Psychological first aid, 331, 427–434
- Psychoneuroimmunology, 82, 90
- Psychophysiological disease, 9
- Psychosomatic disease, 9, 55, 56, 58,  
 59, 95, 131, 296, 448
- Psychosomatic disease, stress  
 and arousal-related  
 conflict theory of, 58  
 Everly and Benson's disorders of arousal  
 model of, 59–61  
 General Adaptation Syndrome model of,  
 54–55  
 Kraus and Raab's hypokinetic model of,  
 56–57  
 Lachman's behavioral model of, 55  
 Schwartz's dysregulation model of, 57–58  
 Sternbach's model of, 56  
 target-organ overstimulation in, 58, 61–63

- Psychotherapy  
   Acceptance and Commitment Therapy, 166–168  
   Beck's cognitive therapy model of, 161–163  
   biofeedback use with, 274  
   cognitively-based, 160–168  
   cognitive primary concept of, 158–160  
   control as component of, 164, 168  
   Ellis's rational-emotive model of, 160–161  
   hypnosis as adjunct to, 139  
   Meichenbaum's stress inoculation training model of, 163–166  
   personologic, 133–134, 136, 139  
   as positive psychology, 151, 152  
   for posttraumatic stress disorder, 416, 417  
   religious and spiritual themes in, 333  
   during World War I, 256, 295  
 Psychotraumatology, 413  
 Psychotropic drugs, pharmacology of, 318  
 Putamen, 205
- Q**
- Quetiapine (Seroquel®), 326
- R**
- Rahe, R., 105, 122, 385, 391  
 Raphael, B., 430–432  
 RAPID, 433, 434  
 Rational-emotive therapy (RET), 160, 161, 168, 258, 261, 264  
 Rational stage directed hypnotherapy (RSDH), 258, 260, 264  
 Raynaud's disease, 71, 75, 94, 178, 274  
 Reactivity, psychological, type A  
   behavior-related, 58  
 Reality control, relaxation  
   training-related loss of, 90  
 Recovery, from illness effect of  
   control on, 338  
   effect of religious beliefs on, 338  
 Recovery Locus of Control Scale, 134  
 Regression, 257, 263, 338, 417  
 Rehabilitation patients, perceived  
   control in, 334, 339  
 Relational Frame Theory (RFT), 167  
 Relaxation and Stress Reduction  
   Workbook (Davis, Eshelman, and McKay), 251  
 Relaxation response  
   cardiovascular effects of, 188, 191  
   clinical precautions for use of, 190–193  
   definition of, 173–174  
   limbic hypersensitivity, 179–182  
   during meditation, 173  
   neuronal plasticity, 182–186  
   neurophysiological rationale  
     for use of, 173–193  
   physiology of, 187–189  
   psychotherapeutic effect of, 188  
   respiratory effects of, 187  
   side effects of, 190–192  
 Relaxation response (Benson), 186, 192  
 Relaxation response patient's adherence to, 319  
 Relaxation techniques  
   originator of, 238  
   selection of, 189  
 Relaxation training, of nursing-home  
   residents, 147  
 Religion differentiated from spirituality  
   emotional health effects of, 335–337  
   physical health effects of, 338–340  
   therapeutic effects of, 341–342  
 Religious Coping Index, 337  
 Remembered wellness, 334  
 Remeron® (mirtazaprine), 323, 325  
 REM sleep, 369–372, 375, 378  
 Repressed ideation, relaxation training-related  
   freeing of, 190  
 Resilience, 2, 119, 143–152  
 Resilient leadership, 150–152  
 Respiratory disorders disability-adjusted  
   life years associated with  
   allergy, 76  
   bronchial asthma, 76–77  
   hyperventilation, 77  
   stress-related, 67–95  
 Respiratory patterns, 94, 226, 309  
   voluntary control of  
     action mechanisms of, 225–226  
     basic patterns of, 224–225  
     clinical research in, 226–227  
     history of, 223–224  
     implementation of, 227–232  
     precautions for use of, 227  
 Respiratory rate, meditation-related  
   decrease in, 207  
 Response mechanisms stereotypy, 42  
 Resting energy requirements, 349  
 RET. *See* Rational-emotive therapy (RET)  
 Reticular activating system, 92, 176, 180, 275  
 Reticular formation, functions of, 23  
 Reverberation, neurological, 180–181  
 Revivification, 257  
 RFT. *See* Relational Frame Theory (RFT)  
 Rheumatoid arthritis, 78, 210, 302

- Rhinencephalon, role in emotional arousal, 175
- Right anterior insula, 205
- Risperdal® (risperidone), 326
- Risperidone (Risperdal®), 326
- Rockport One-Mile Fitness Walking Test, 303
- Roosevelt, E., 157
- Rosch, P., 6, 84, 331
- Rossi, E., 257
- RSDH. *See* Rational stage directed hypnotherapy (RSDH)
- Rush Medical School, 238
- S**
- SAD. *See* Social Anxiety Disorder (SAD)
- Salt, stress-associated consumption of, 352, 444
- SASRQ. *See* Stanford Acute Stress Reaction Questionnaire (SASRQ)
- Satori, 206
- Saturday Review, 90
- Schemas, 161, 162, 418
- Schizoid personality, 135, 211
- Schizophrenia, 86–87, 92, 93, 95, 114, 210, 240, 276, 318, 326, 354, 413
- Schwartz's dysregulation model, of psychosomatic disease, 57–58
- Screen for Posttraumatic Stress Symptoms (SPTSS), 120
- Sedative-hypnotics, 327–328
- Selective serotonin reuptake inhibitors (SSRIS), 322–325, 416
- Selenium, antioxidant activity of, 356
- Self-concept effect of exercise on, 299, 301, 306, 309  
effect of physical activity on, 299, 301, 306, 309
- Self-efficacy  
in chronically-ill patients, 148–149  
relaxation response-related, 188, 189
- Self-hypnosis, 262, 263
- Self-report relaxation training form, 227
- Seligman, M., 148, 151
- Selye, H.  
early life and academic training of, 438  
experimental surgical skills of, 439, 442–444  
stress concept development by, 331, 437–446
- Sensitization, behavioral, 183
- Sensorimotor training, 276
- Septal-hippocampal-amygdala complex, 30, 410  
in posttraumatic stress disorder, 410
- September, 1, 5, 337, 376, 379, 392, 402
- Septum anatomy of  
role in emotional arousal, 30, 32
- Serax® (oxazepam), 319, 320
- Serentil (mesoridazine), 326
- Seriousness of Illness Rating Scale (SIRS), 113, 123
- Seroquel® (quetiapine), 326
- Serotonergic neuronal tracts, 318
- Serotonin  
antidepressant-induced increase in, 321–322  
carbohydrates as source of, 348  
deficiency of, as depression cause, 86  
neuronal pathways of, 19  
in posttraumatic stress disorder, 411, 416  
synthesis of, 36
- Sertraline (Zoloft®), 323, 324
- Serzone (nefazodone), 323
- Shakespeare, W., 157
- Shapiro, F., 418, 419
- Shell shock, 256
- Shiftworkers, 372–374, 378
- Sidis, B., 256
- Simple carbohydrates, 348, 360
- Sinequan® (doxepin), 324
- SIRS. *See* Seriousness of Illness Rating Scale (SIRS)
- Sixteen Personality Factor Questionnaire (16-PF), 114–115, 123
- Skin disorders, stress-related, 78
- Skin potentials (SP), 108, 323
- Sleep, 85, 91, 206, 208, 214, 256, 260, 262, 272, 275, 318–320, 324, 331, 336, 337, 353, 357, 360, 369–379, 392, 394, 404, 416  
apnea, 371  
disturbances, pharmacological therapy for, 372  
hygiene, 374, 377  
inertia, 375
- Sloan-Kettering cancer center, 445
- Slow-wave sleep (SWS), 370, 371
- Small intestine, anatomy  
and physiology of, 68
- Smokers, vitamin C intake of, 355
- Social anxiety disorder (SAD), 205, 322
- Social cognitive theory, 148
- Social learning theory, of control, 299
- Social phobia, pharmacological therapy for, 324
- Social Readjustment Rating Scale (SRRS), 105, 106, 122
- Socrates, 162, 163
- Socratic dialogue, 162

- Sodium absorption and excretion of, 36  
 role in neural transmission, 18–21
- Sodium nitrate (NA<sup>+</sup>), 19, 20
- Soft drinks, caffeine content of, 357–358
- Soldiers, crisis intervention with, 428, 429
- Soldier's heart, 256
- Somatic disorders of arousal, 178, 192
- Somatic nervous system, 23
- Somatic relaxation, meditation-induced, 207, 208
- Somatoform disorders, 10
- Somatotropic axis, 35, 37–38, 47
- Somatotropin-releasing factor (SRF), 37
- Specific types of cancer, 86
- Spinal cord, function of, 22, 83, 318
- Spiritual doubts, 341
- Sports performance training, 296
- SRF. *See* Somatotropin-releasing factor (SRF)
- Stages of sleep, 369, 371
- STAI. *See* State-Trait Anxiety Inventory (STAI)
- Stanford Acute Stress Reaction Questionnaire (SASRQ), 117
- State-Trait Anxiety Inventory (STAI), 118, 119, 123, 260, 261
- 12-step programs, 341
- Sternbach's model, of psychosomatic disease, 56
- Stimulation, hypersensitivity to, 175, 179
- Stimuli psychosocial  
 physical reactions to, 30  
 threatening, 30, 33
- Stomach, anatomy and physiology of
- Stoyva, J.M., 56, 61, 108, 109, 134, 188, 261, 270–272
- STRAIN. *See* Stress and Adversity Inventory (STRAIN)
- Strain, 6, 56, 57, 76, 106, 182, 228, 241, 243, 251, 294, 297, 305, 307, 308, 357, 431, 440, 441
- Stress *See also* Stress response beneficial effects of  
 biologic, 440  
 chronic, effect on immune function, 88–89  
 cognitive-affective reactions to  
 definition of, 5–6  
 effect on immune system  
 (*see* Psychoneuroimmunology)  
 historical references to, 437  
 major concepts of, 437–446  
 optimal level of, 11  
 physical expression of (*see also* Exercise)  
 activation, 293, 294  
 effect on target organs, 284  
 measurement of, 123  
 preoperative, 259  
 psychological effects of, 123  
 public health implications of, 437  
 somatic symptoms of, 337  
 suppression of, 359  
 treatment for, 139
- Stress (Selye), 442
- Stress and Adversity Inventory (STRAIN), 106
- Stress Audit Questionnaire, 113
- Stressful Life Experiences Screening (SLES), 105
- Stress inoculation training, 163–166, 168, 419
- Stress management, 59, 90, 139, 143, 144, 151, 166, 168, 189, 190, 209, 255, 257, 259–262, 264, 277, 299, 303, 307–309, 339, 427, 430, 432, 451  
*See also* Relaxation response  
 patient's adherence to
- Stressor measurement scales, 105–106, 122
- Stressors  
 biogenic stimulant characteristics of, 7–8  
 definition of, 3–8, 385–386  
 environmental, psychological effects of, 7, 28, 45, 83  
 generic, 259  
 psychosocial  
 cognitive-affective processes affecting, 7  
 cognitive interpretation of, 28–30  
 effect on immune function, 83–85  
 stress-inhibiting properties of, 27
- Stress-related disease  
 cardiovascular disorders, 71–76  
 coronary artery disease, 75–76  
 essential hypertension, 74  
 gastrointestinal disorders, 67–71  
 esophagitis, 71  
 gastroesophageal reflux, 68  
 irritable bowel syndrome, 70–71  
 peptic ulcers, 68–70  
 ulcerative colitis, 70  
 musculoskeletal disorders, 77–78  
 myocardial ischemia, 75–76  
 psychological disorders  
 as disorders of arousal, 174–175  
 personologic psychotherapy for, 133–134  
 respiratory disorders  
 allergy, 76  
 bronchial asthma, 76–77  
 hyperventilation, 77  
 skin disorders, 78  
 vasospastic phenomena, 75

- Stress response  
 anatomy and physiology of, 17–47  
 beneficial effects of, 350–351  
 immune system in, 78–91  
 measurement of  
   cardiovascular measures, 109–110  
   cognitive-affective correlate scales, 106  
   coping assessment, 121  
   electrodermal measures, 107–108  
   electromyographic measures, 108–109  
   endocrine axis assessment, 111–112  
   law of initial values of, 121  
   multiaxial nature of, 30, 41, 43  
   neural axes assessment, 107  
   neuroendocrine axis assessment, 33–40  
   nonspecificity of, 9  
   pattern specificity of, 40  
   physiological measures, 112, 122  
   physiological mechanisms of, 30, 37, 44, 47  
   stressor scales, 105–106  
   systems model of, 24–43  
   target-organ effects assessment, 113–120  
   treatment model for  
   treatment model for: multiaxial model, 1  
   treatment model for: patient's adherence to, 319, 450  
   neurological foundations of, 17–24  
   treatment protocol for, 449–450
- Striated muscle, in limbic arousal, 181, 298
- Structural breathing, 317
- Subjective Stress Scale, 118
- Sudden death, 4, 34, 178, 391
- Sufis, 203
- Sugar, stress-associated consumption of, 259
- Suggestibility enhanced, hypnotic, 263
- Suicide, disability-adjusted life years associated with, 4
- Supraconsciousness, 206, 207
- Surgical patients  
 hypnosis use in, 256, 260  
 recovery of, effect of perceived control on, 338
- Survival of the Wisest* (Salk), 3
- Swimming, therapeutic, 295
- SWS. *See* Slow-wave sleep (SWS)
- Syllabus on Hypnosis and a Handbook of Therapeutic Suggestions, A* (American Society of Clinical Hypnosis Education and Research Foundation), 259
- Sympathetic hyperreactivity, 178
- Sympathetic nervous system  
 anatomy and function of, 31, 32, 41  
 end-organ effects of, 32  
 ergotropic tuning of, 179–180  
 neural activation function of, 32  
 preferential responsiveness of, 179
- Sympathoadrenomedullary system (SAM), 34, 37, 47, 74, 411  
 in posttraumatic stress disorder, 411
- Sympathomimetic characteristics, of biogenic stressors, 7
- Sympathomimetics stress-inducing, 448  
 vasoactive pressure to, 448
- Symptom Checklist-Revised (SCL-90-R), 120
- “Syndrome of just being sick,” 6, 33
- Systems model, of the stress response  
 cognitive-affective domain of, 28–30  
 general adaptation syndrome concept of, 39–40  
 neural axes element of, 31–32  
 neuroendocrine axis of, 33–40  
 neurological triggering mechanisms element of, 30–31  
 stressor events element of, 27  
 target-organ activation concept of, 41–43
- T**
- Taoist, 202
- Target-organ disease. *See* Psychosomatic disease
- Target organs neural innervation of activation, 41–43  
 effect of stress on, 113–120  
 measurement of, 113
- Taylor Manifest Anxiety Scale (TAS), 117, 118, 123
- TCAS. *See* Tricyclic antidepressants (TCAS)
- T cells, 79–82  
 trauma-related decrease in, 409
- Tea, caffeine content of, 357–385
- Temperature-based biofeedback, 273–275
- Temporal lobe disorders, 177
- Temporomandibular disorders, 272  
 electromyographic biofeedback treatment for, 271–273
- Tenormin (atenolol), 327
- Terrorism crisis intervention for crisis management briefing response to, 427  
 definition of, 427  
 intensity of psychological impact of, 431–433

- Test anxiety, hypnosis as treatment for, 260  
 Test Anxiety Scale, 260  
 Testosterone  
   in posttraumatic stress disorders, 130  
   type A behavior-related release of, 130  
*Textbook of Glandular Physiology and Therapy* (American Medical Association), 445  
 Thalamo-reticular system, 181  
 Thalamus, 23, 32, 175  
 Theobromine, 27  
 Theophylline, 27  
 Theta wave activity, 206, 275  
 Thinking, critical, suspension of, 257  
 Thioridazine (Mellaril), 326  
 Thiothixene (Navane), 326  
 Thomas, C., 131  
 Thorazine (chlorpromazine), 326  
 Thorndike, E., 269  
 Thoughts, automatic, 161, 162  
 Threatening stimuli, 259  
 Threat, perception of, 161, 259  
 Three Mile Island nuclear accident, 90–91, 375  
 Thyroid axis, 35, 38, 47  
 Thyroid-stimulating hormone (TSH), 38  
 Thyrotropin-related factor, 38  
 Thyroxine, 38  
 Thyroxine-binding globulin (TBG), 38  
 Time sense distortion, 257  
 Titchner, E., 238  
 Tofranil® (imipramine), 322, 323  
 Torticollis, 280  
 Transactional model, 159  
 Transcendental meditation (TM), 202, 203, 261  
 Tranxene® (clorazepate), 319, 320  
 Tranylcypromine (Parnate®), 322, 323  
 Trauma definition of  
   effect on immune function, 90–91  
   prevalence of, 401–402  
 Traumatic events, writing about, 392  
 Trazodone, 416  
 Triazolam (Halcion®), 319  
 Tricyclic antidepressants (TCAS), 322–324, 416  
 Triiodothyronine (T3), 38  
 Trophotropic response  
   exercise-related, 298  
   relaxation training-related, 298  
 Tryptophan, 318, 349, 353, 360–361, 378  
 TSH. *See* Thyroid-stimulating hormone (TSH)  
 Twain, M., 157  
 Type A personality, 128  
 Tyramine, 322  
 Tyrosine hydroxylase, 36, 421
- U**  
 UCLA Loneliness Scale, 88  
 Ulcerative colitis, 67, 70, 93, 278  
 United States Department of Agriculture (USDA), 348–350, 355, 358, 360  
 University of California, 184  
 University of Chicago, Rush Medical School, 238  
 University of Montreal, Institute of Experimental Medicine and Surgery, 439  
 University of Prague, 6  
 University of Vienna, 255  
 Urinary incontinence, electromyographic biofeedback treatment for, 272  
 Urticaria, 78  
 USDA. *See* United States Department of Agriculture (USDA)  
 U.S. Surgeon General, 4
- V**  
 Valium (diazepam), 319, 320  
 Vanillylmandelic acid (VMA), 111  
 Vasoactive substances, 459  
 Vasopressin, 38, 411  
 Vasospastic phenomena, 75, 94  
 Vedantism, 202  
 Vegetables, carotenoid-containing, 302, 347–350, 352, 354, 355, 360  
 Venlafaxine (Effexor), 323, 325  
 Ventricular fibrillation, 178  
 Vietnam veterans, posttraumatic stress disorder in, 409, 413, 418  
 Vinci, L.D., 1, 447  
 Vistaril (hydroxyzine), 327  
 Vitamin C, antioxidant activity of, 354–356  
 Vitamin E, antioxidant activity of, 354–356  
 Vitamins, B12 carbohydrates as source of, 348  
 VMA. *See* Vanillylmandelic acid (VMA)  
 Voluntary control, 223–233  
 Voluntary hyperventilation, 228
- W**  
 Walking cardioprotective effects of  
   as exercise, 295, 303, 304  
   psychological benefits of, 342  
 Walter Reed Army Medical Center, 445  
 War neurosis, 403

- WAS. *See* World Assumption Scale (WAS)  
 Water intake, during stress, 351  
 Water retention, 39  
 Watson, J., 269  
 Ways of Coping Checklist, 121, 123  
*Weltanschauung*, 412  
 WHI. *See* Women's Health Initiative (WHI)  
 "Whirling dervishes," 203  
 White blood cells, 79, 82, 87, 91  
 Whole-body breathing, 228  
 Wilkins, L., 445  
 Withdrawal syndromes, 177  
 Wolf, S., 146  
 Wolpe, J., 238, 258  
 Women's Health Initiative (WHI), 338  
 Worden, J.W., 387, 393–396  
     four tasks of mourning, 385  
 World Assumption Scale (WAS), 106  
 World Health organization (WHO), 57, 294,  
     301, 358, 377  
 World Trade Center, terrorist attack  
     against, 5, 392, 402  
 Writing, about traumatic events, 106, 143,  
     144, 376, 379, 392, 396, 408, 432,
- X**  
 Xanax (alprazolam), 319, 320
- Y**  
 Yale University, 57  
 YMCA exercise testing protocol, 303  
 Yoga, 202, 203, 213, 223, 232, 296,  
     300, 306, 418  
     Hatha, 203, 223  
 Yohimbine, 7, 27  
*You Must Relax* (Jacobson), 251
- Z**  
 Zajonc, R.B., 159  
 Zazen, 202, 226  
 Zen, 202, 203, 207, 213  
     *koan* of, 203  
 Zoloft (sertraline), 323, 324  
 Zona fasciculata, 35  
 Zona glomerulosa, 36  
 Zona reticularis, 35  
 Zyprexa (olanzapine), 326